Clinical Trial Update: FX-322 in Sensorineural Hearing Loss [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for FX-322 in sensorineural hearing loss has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sensorineural Hearing Loss

Drugs mentioned

• FX-322

Snippet

Sponsor: Frequency Therapeutics | Conditions: Sensorineural Hearing Loss | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-14